Selective CB2 agonist LEI-101 relieves pain across rat models without opioid-like liabilities
- LEI-101 is a selective CB2 receptor agonist; in human and rat receptor assays it bound tightly, acted as a functional agonist, and showed clear preference over CB1.
- Given systemically to rats, it eased heightened pain sensitivity in osteoarthritis, nerve injury, postoperative and chronic inflammatory models in a dose-dependent way.
- Blocking CB2 abolished the benefit, whereas CB1 or mu-opioid blockers did not, so the effect is not opioid-dependent. At analgesic doses movement was unaffected, and repeated dosing did not produce opioid-like tolerance.
💡 Points Based on the abstract
CB2 has burned this field repeatedly: clean rodent analgesia, then nothing in patients. What I'd press on is that this package is unusually tidy on mechanism and tolerance, yet silent on exposure at efficacious dose and on human target evidence. Rat pain readouts are reflex-driven and generous. I'd want unbound exposure and a non-reflex endpoint before calling this worth a clinical bet.
LEI‐101 produces broad‐spectrum analgesia in preclinical pain models ↗